Dr. Kerry Fowler

Dr. Fowler has over 30 years of experience as a medicinal chemist.  He received his Ph.D. in organic chemistry from Yale University in synthetic methods and natural products synthesis.  As a postdoctoral fellow at the Massachusetts Institute of Technology he applied synthetic methods to the study of chemical carcinogenesis.  As a group leader at G.D. Searle & Co. he conducted structure-activity studies of antiarrhythmic and antihypertensive agents.

After moving to ICOS Corporation he built the medicinal and process chemistry groups and served as Director of Medicinal Chemistry.  His team and their biology colleagues placed eight projects into development, seven of which began as high-throughput hits which were validated and optimized in-house.  Four candidates advanced to clinical trials including one developed and brought to market by Calistoga and Gilead (Zydelig®, idelalisib).  Another HTS hit (IC-87201) was a groundbreaking inhibitor of the PSD95-nNOS interaction discovered by Dr. Lai and formed the basis for Anagin’s current drug discovery efforts.  Dr. Fowler was also involved in the chemical development of Cialis® (tadalafil) and the Lilly-ICOS vs. Pfizer litigation.